Sonnet BioTherapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Disclosures About Fair Value - Schedule of Fair Value of Measured Assets and Liabilities (Details)

Disclosures About Fair Value - Schedule of Fair Value of Measured Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value Disclosure [Line Items]
Available-for-sale securities	$ 35,362hotr_InvestmentsFairValue	$ 55,112hotr_InvestmentsFairValue
Embedded conversion feature	1,610,900us-gaap_DerivativeLiabilities	2,146,000us-gaap_DerivativeLiabilities
Quoted Prices In Active Markets Of Identical Assets (Level 1) [Member]
Fair Value Disclosure [Line Items]
Available-for-sale securities	35,362	55,112
Embedded conversion feature
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Disclosure [Line Items]
Available-for-sale securities
Embedded conversion feature
Significant Unobservable Inputs (Level 3) [Member]
Fair Value Disclosure [Line Items]
Available-for-sale securities
Embedded conversion feature	$ 1,610,900	$ 2,146,000

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References + Details